Drugs / Reiferon Retard
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01896609 | Jun 2013 → Jan 2015 | chronic hepatitis C virus infection | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
| Phase 4 | NCT01649245 | Aug 2012 → Aug 2014 | chronic hepatitis C virus infection | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Reiferon Retard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01896609 ↗ |
| Known as | Pegylated interferon alfa-2a (Reiferon Retard 160 µg ) | “Pegylated interferon alfa-2a (Reiferon Retard 160 µg ®)” NCT01896609 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated Hansenula-derived recombinant interferon α 2a” NCT01649245 ↗ |
| Route | Subcutaneous | “Reiferon Retard® 160 µg weekly by subcutaneous injection” NCT01649245 ↗ |